证券代码：603001 证券简称：奥康国际 公告编号：临 2025-023 浙江奥康鞋业股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律连带责任。 重要提示： ● 浙江奥康鞋业股份有限公司（以下简称"公司"）股票于 2025 年 7 月 11 日、7 月 14 日、7 月 15 日连续 3 个交易日内收盘价格涨幅偏离值累计达到 20%，根据《上海证券交易所交易规则》相关规定，属于股票交易异常波动的情 形。 ● 经公司自查并向控股股东及实际控制人书面核实，截止本公告披露日， 除已公开披露的事项外，公司、控股股东及实际控制人不存在应披露而未披露 的重大信息。 ● 公司预计 2025 年半年度实现归属于母公司所有者的净利润约为-8,700 万元，与上年同期相比，亏损加大。敬请广大投资者理性投资，注意二级市场 交易风险。 一、股票交易异常波动的具体情况 公司股票交易于 2025 年 7 月 11 日、7 月 14 日、7 月 15 日连续 3 个交易日 内日收盘价格涨幅偏离值累计达到 20%，根据《上海证券 ...

Core Viewpoint - Wang Zhentao, the founder of Aokang International, is facing significant financial difficulties due to failed cross-industry ventures, leading to plans to transfer control of Kanghua Biological, a company he established, to alleviate cash flow pressures [1][2][6]. Group 1: Financial Performance - Kanghua Biological reported a revenue of 14.32 billion yuan in 2024, a year-on-year decline of 9.23%, and a net profit of 3.99 billion yuan, down 21.71% [2]. - In the first quarter of 2025, Kanghua Biological's total revenue was 1.38 billion yuan, a decrease of 55.7%, with a net profit of 20.71 million yuan, down 86.14% [3]. - The stock price of Kanghua Biological has dropped significantly from a peak of 414 yuan to 72.01 yuan per share, resulting in a market capitalization reduction to 9.574 billion yuan [3]. Group 2: Ownership and Control Changes - Wang Zhentao is planning to transfer control of Kanghua Biological, which has been a significant part of his business portfolio since its establishment in 2004 [2]. - The stock of Kanghua Biological was suspended from trading starting July 14 due to the announcement of the potential change in control [2]. Group 3: Investment Losses and Challenges - Aokang International has incurred substantial losses from various investments, including over 200 million yuan in a cross-border e-commerce platform and a failed semiconductor acquisition [1][4][5]. - The company has reported net losses of 679 million yuan over the past three years, indicating ongoing financial struggles [1][6]. Group 4: Share Pledge and Regulatory Issues - Wang Zhentao has pledged a significant portion of his shares in both Aokang International and Kanghua Biological, with 89.2% and 71.91% of shares pledged, respectively [7]. - Regulatory penalties were imposed on Wang Zhentao and related companies for misappropriating funds from Aokang International, totaling 1.67 billion yuan and 950 million yuan in 2021 and 2022 [8].

Summary of Key Points Core Viewpoint - Zhejiang Aokang Footwear Co., Ltd. expects a significant net loss of approximately 87 million yuan for the first half of 2025, primarily due to macroeconomic downturns, weak consumer demand, and intensified industry competition [1]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of approximately -87 million yuan for the first half of 2025 [1]. - The previous year's net profit attributable to shareholders was -19.83 million yuan, with a net profit of -57.57 million yuan after deducting non-recurring gains and losses [1]. - The expected revenue for the current period is 1.081 billion yuan, representing a decline of about 21% compared to the same period last year [1]. Group 2: Financial Status - The company reported a loss per share of -0.0494 yuan in the previous year [1]. - The current performance forecast has not been audited by a registered accounting firm [1].

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company forecasts a significant net loss for H1 2025, with net profit attributable to shareholders estimated at **-87 million RMB** and the loss after non-recurring items at **-116 million RMB** 2025 Semi-Annual Performance Forecast | Indicator | Forecast Amount (RMB) | | :--- | :--- | | Performance Forecast Period | January 1, 2025 to June 30, 2025 | | Net Profit Attributable to Parent | Approx. -87 million RMB | | Net Profit Attributable to Parent (Excluding Non-recurring Items) | Approx. -116 million RMB | - This performance forecast is unaudited by a certified public accountant[2](index=2&type=chunk) [Prior Period Performance Comparison](index=1&type=section&id=II.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Position) The company's losses significantly expanded compared to the prior year, with H1 2024 net profit attributable to the parent at **-19.83 million RMB** and the loss after non-recurring items at **-57.57 million RMB**, indicating deteriorating profitability 2024 Semi-Annual Financial Performance | Indicator (H1 2024) | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Parent | -19.83 million RMB | | Net Profit Attributable to Parent (Excluding Non-recurring Items) | -57.57 million RMB | | Earnings Per Share | -0.0494 RMB | [Analysis of Performance Change Reasons](index=1&type=section&id=III.%20Main%20Reasons%20for%20Current%20Period%20Performance%20Change) The expanded loss is primarily due to a significant decline in operating revenue, influenced by macroeconomic downturn, weak consumer demand, and intensified industry competition, leading to an estimated **21% year-on-year decrease** in H1 2025 revenue - Performance decline is attributed to multiple external factors including macroeconomic downturn, weak consumer demand, and intensified industry competition[4](index=4&type=chunk) 2025 Semi-Annual Operating Revenue Forecast | Indicator | H1 2025 Estimate | Year-on-Year Change | | :--- | :--- | :--- | | Operating Revenue | 1.081 billion RMB | Approx. 21% decrease | - The company explicitly states that the decrease in operating revenue is the primary cause of the operating performance loss[5](index=5&type=chunk) [Risk Warning and Audit Communication](index=2&type=section&id=IV.%20Risk%20Warning) The company advises investors that this performance forecast is based on preliminary, unaudited data, though pre-communication with the accounting firm indicates no other significant uncertainties affecting its accuracy - This performance forecast data represents preliminary calculations by the company's finance department and has not been audited by an accounting firm[6](index=6&type=chunk) - The company has pre-communicated with the accounting firm regarding the performance forecast, and both parties believe there are no other significant uncertainties affecting the accuracy of the forecast content[6](index=6&type=chunk) [Other Explanations](index=2&type=section&id=V.%20Other%20Explanations) The company reiterates that this forecast data is preliminary, with final accurate financial data subject to the officially disclosed 2025 semi-annual report, advising investors to be aware of investment risks - The final accurate financial data will be subject to the company's officially disclosed 2025 semi-annual report, and investors are advised to be aware of investment risks[7](index=7&type=chunk)

Core Viewpoint - The return of Wang Zhentao as chairman and president of Aokang International is seen as a dual measure for "rescue" and "breakthrough" amid the company's ongoing operational difficulties, with significant challenges ahead [1][8]. Company Performance - Aokang International has faced continuous losses in its main business from 2019 to 2024, with a cumulative net profit loss of 899 million yuan [1][6]. - The company's net profit and non-recurring net profit continued to decline in the first quarter of 2025, with losses of 44 million yuan and 48 million yuan, respectively [6]. Governance and Internal Control - Wang Zhentao resigned as chairman in December 2024 due to penalties for unauthorized fund usage and delayed disclosures, indicating a need for governance reconstruction [2][7]. - As of June 26, 2025, Wang's share pledge ratio for Aokang International was 99.08%, with 60 million shares pledged out of 60.56 million shares held [7][8]. Industry Context - The footwear industry is contracting, with China's shoe production declining from 4.618 billion pairs in 2016 to 3.524 billion pairs in 2021, and projections suggest a further reduction to 1.7 billion pairs by 2026 [8]. - Aokang International has attempted various strategies to innovate and revitalize its product offerings, including launching a new line of sports shoes and collaborations with brands like Marvel, but these efforts have yielded limited financial success [8].

Group 1 - The core viewpoint of the article highlights the shift in consumer demand for footwear from "warm and durable" to "comfortable and personalized," indicating a transformation in the growth logic of traditional footwear brands [1] - Aokang International has established China's first foot shape database and created a Comfort Footwear Research Institute, accumulating hundreds of patented technologies to develop shoe lasts that fit the arch and pressure distribution of Asian feet, turning "fit" into a data-driven science [3] - The 3.0 series of sports shoes embodies this concept, featuring an EVA ultra-light foam outsole that reduces weight by 50% compared to ordinary soles, and incorporates Dyneema® high-strength fiber material, enhancing tear resistance by three times [3] Group 2 - In terms of R&D investment, Aokang has collaborated with Italian materials giant XL EXTRALIGHT® to develop ultra-light outsole technology, pushing the performance limits of traditional EVA materials [5] - The implementation of the "comfort" strategy relies on production efficiency and precise channel reach, with smart factories introducing 3D design systems and CNC equipment to enhance production processes [5] - Aokang is also updating its flagship store image to convey that "comfort" is not just a product attribute but a lifestyle proposition, utilizing AI technology to create targeted short videos for the 25-35 age demographic [5]

Core Points - The article outlines the information disclosure policy of Zhejiang Aokang Footwear Co., Ltd, focusing on the conditions under which the company can postpone or exempt disclosures to protect its interests and those of investors [1][2][5] - The policy is established in accordance with the Securities Law of the People's Republic of China and the Shanghai Stock Exchange Listing Rules, ensuring compliance with legal and regulatory requirements [1][5] Group 1 - The company can postpone disclosure if the information is uncertain, classified as a temporary business secret, or if timely disclosure may harm the company's interests or mislead investors, provided that insiders have signed confidentiality agreements [1][2] - The company can exempt disclosure if the information is classified as a state secret or business secret, and disclosing it would violate confidentiality laws or harm the interests of the company and investors [2][5] - The definition of "business secret" includes information that is not publicly known, provides economic benefits, and is protected by confidentiality measures, while "state secret" refers to information related to national security that is restricted to a limited audience [2][5] Group 2 - The company must ensure that postponed disclosures meet specific conditions, including the absence of information leaks, written confidentiality commitments from insiders, and no abnormal trading activity in the company's stock [3][4] - If the reasons for postponement or exemption are no longer valid or the time limit has expired, the company must promptly disclose the relevant information and the circumstances surrounding the postponement or exemption [4][5] - The company has established a responsibility accountability mechanism for information disclosure, ensuring that any failure to comply with the policy will result in appropriate disciplinary actions against responsible personnel [4][5]

作为浙江奥康鞋业股份有限公司（以下简称"公司"）的独立董事，根据中 国证券监督管理委员会《上市公司独立董事规则》及《公司章程》的有关规定， 就公司 2025 年 6 月 30 日召开的第八届董事会第十七次会议审议的《关于聘任公 司总裁的议案》发表独立意见如下： 浙江奥康鞋业股份有限公司 独立董事关于聘任公司总裁的独立意见 我们一致同意聘任王振滔先生为公司总裁。 独立董事：周俊明 Bingsheng Teng 林宗纯 2025年6月30日 1/ 1 公司聘任总裁的相关程序符合有关法律、法规和《公司章程》的相关规定。 不存在被中国证监会确定为市场禁入者，并且禁入尚未解除的现象，亦不存在被 证券交易所公开认定为不适合担任上市公司高级管理人员的情形。经审阅王振滔 先生的个人简历等相关资料，我们认为王振滔先生具备担任公司总裁的任职条件 和履职能力。 ...

浙江奥康鞋业股份有限公司 信息披露暂缓与豁免制度 第一章 总 则 第一条 为规范浙江奥康鞋业股份有限公司（以下简称"公司"）信息披露暂 缓与豁免行为，督促公司及相关信息披露义务人（以下简称"信息披露义务人"） 依法合规地履行信息披露义务，保护投资者的合法权益，根据《中华人民共和国 证券法》、《上海证券交易所上市规则》（以下简称"《上市规则》"）、《上海证券交 易所上市公司信息披露暂缓与豁免业务指引》等法律、法规、规章和《浙江奥康 鞋业有限公司章程》（以下简称"《公司章程》"）、公司《信息披露管理制度》的 规定，结合公司信息披露工作的实际情况，制定本制度。 第二条 本公司按照《上市规则》及交易所其他相关业务规则的规定，办理 信息披露暂缓、豁免业务的，适用本制度。 第三条 本公司拟披露的信息存在《上市规则》及交易所其他相关业务规则 中规定的可暂缓、豁免披露情形的，由公司自行审慎判断，并接受上海证券交易 所对有关信息披露暂缓、豁免事项的事后监管。 本公司及相关信息披露义务人应当审慎确定信息披露暂缓、豁免事项，不得 随意扩大暂缓、豁免事项的范围 第四条 本公司拟披露的信息属于下列情形之一的，可以暂缓披露： （一）公司 ...

证券代码：603001 证券简称：奥康国际 公告编号：临 2025-020 浙江奥康鞋业股份有限公司 关于公司高级管理人员辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江奥康鞋业股份有限公司（以下简称"公司"）董事会近日收到公司副总 裁陈瑞福先生的辞职报告。由于个人原因，陈瑞福先生申请辞去公司副总裁职务， 辞职后不再担任公司任何职务。 根据《公司法》及《公司章程》等相关规定，陈瑞福先生的书面辞职报告自 送达公司董事会之日起生效。陈瑞福先生担任副总裁所负责的相关工作已完成交 接，其离任不会影响公司相关工作的正常开展。截至本公告披露日，陈瑞福先生 未持有公司股票。 公司董事会对陈瑞福先生在任职副总裁期间为公司发展所做的贡献表示衷 心的感谢！ 特此公告。 浙江奥康鞋业股份有限公司 董事会 2025 年 7 月 1 日 1 / 1 一、提前离任的基本情况 | | | | | 原定任期 | | | 是否继续在上 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- ...